Application of small molecule targeted inhibitors in the preparation of drugs for treating tumors

By targeting the inhibition or activation of the interaction between PKM2 and ALDH1A3, the metabolic pathway of tumor cells is regulated, and the problem of insufficient specificity of PKM2 inhibitors in the prior art is solved, and effective inhibition and therapeutic effects on tumor cells are achieved.

CN115887467BActive Publication Date: 2024-11-29BEIJING NEUROSURGICAL INST
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211693691.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-28
Publication Date
2024-11-29
Estimated Expiration
2042-12-28

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0004022454350000021
    Figure BDA0004022454350000021
  • Figure BDA0004022454350000031
    Figure BDA0004022454350000031
Patent Text Reader

Abstract

The present invention relates to the field of biopharmaceuticals, and in particular to the use of small molecule targeted inhibitors in the preparation of drugs for treating tumors. The present invention provides the use of targeted inhibitors in the preparation of drugs for treating tumors; the targeted inhibitors inhibit the interaction between PKM2 and ALDH1A3. The present invention targets the unique mechanism of PKM2 allosterically activated by ALDH1A3 in tumor tissues, and for the first time develops PKM2 targeted activators and inhibitors with high specificity.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • M2 type pyruvate kinase small molecule activator and application thereof

    CN112156095A

  • Pharmaceutical composition for enhancing sensitivity to anticancer drugs comprising expression or activity inhibitor of PKM2 as an active ingredient

    KR1020150145588A